SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cardiome -- CRME
CRME 2.330-2.1%May 16 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: former_pgs who wrote (12)7/12/2006 6:44:28 PM
From: keokalani'nui  Read Replies (2) of 285
 
ibutilide has 8%+ rate of V-tach, QTc, TdP. x1245 has 0% so far.

x1245, if you treat recent onset AF, the conversion rate goes up to 52%. (Chronic AF conversion rate--small N, is 8%).

I have been thinking the market for x1245 is as big as its safety profile. But just maybe, listening to you--which in my opinion pays--the advertised SEs of existing agents is a big boogey man the company has created for its shareholders.

Not expecting a response, since I think you're tired of this thread, but did your colleagues assume x1245 has the same SE profile as current iv SoC? Or that ibutilide SEs are no biggie? Could explain some things.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News